Stanton Mehr retweeted
Are you ready for #GlobalBiosimilarsWeek? This year’s campaign “Advancing Access to Biosimilars” runs from Nov 11–15. Visit globalbiosimilarsweek.org for the latest information, social media toolkit and downloadable resources you need to help you plan your participation.
Stanton Mehr retweeted
Our healthcare system is dysfunctional. Despite having eight biosimilar competitors, Humira still has a 97% market share! In Kaiser Permanente, there is over 90% usage of an adalimumab bios, similar, which lowers costs, making biologics more affordable to patients.
Biosimilar opportunities and barriers, reported from the 2024 #festivalofbiologicsusa: #PBMs, sustainability, physician reimbursement, development, and more! #biosimilars
wp.me/p7gt6c-7rS
Stanton Mehr retweeted
Learn how the FDA is empowering patients & providers with unbiased biosimilar info through innovative resources & outreach initiatives. Get the latest from Sarah Ikenberry, Senior Communication Advisor at CDER: bit.ly/3uNI2ZV
#Biosimilars #HealthcareInnovation
Stanton Mehr retweeted
We’ll be heading to #Access2024, AAM’s Annual Meeting, on Feb 5–7 for three days of insights and ideas on issues vital to the #generics and #biosimilars industry. Learn more: access.accessiblemeds.org/
Stanton Mehr retweeted
Join us at #Access2024 for the CEOs Unplugged panel by some of the most insightful leaders of the #generics & #biosimilars industry. Gain insights into how these leaders are navigating unprecedented challenges & steering the industry towards solutions. access.accessiblemeds.org/ag…
Stanton Mehr retweeted
[PRESS RELEASE] @BiosimsCouncil submits comments to @US_FDA draft guidance on labeling for #biosimilars and #interchangeable biosimilar products. Read more: biosimilarscouncil.org/news/…
Stanton Mehr retweeted
Shameful #PBM #pharmacy markups for nonbiological generic #drugs vs. @costplusdrugs reflect the ongoing battle for #oncology margin. Wake up, plans!
@CVSHealth $CVS @ExpressScripts $CI @OptumRx $UNH
@joewalkerWSJ @WSJ @46brooklyndata @mcuban
drugch.nl/3sNYkAR
Stanton Mehr retweeted
Today we approved the first biosimilar to treat adults with relapsing forms of multiple sclerosis (MS). fda.gov/news-events/press-an…
Stanton Mehr retweeted
Hillel Cohen and colleagues outline six opportunities to streamline biosimilar development without compromising patient safety or product quality.
#biosimilars #regulatory #OpenAccess
link.springer.com/article/10…
Stanton Mehr retweeted
Warped incentives update: #Humira #biosimilars launch at -5% to -85% lower #WAC list prices 👇
Will big #PBMs support or exclude lower-priced products? Or maybe use step therapy for patients with a clinical contraindication to a higher WAC? 🙄
@StanMehr
drugch.nl/3pLtuYe
Stanton Mehr retweeted
"A new resource from the National Alliance of Healthcare Purchaser Coalitions aims to help plan sponsors adopt biosimilars into their pharmacy benefit plans."
https://teapawt.net/t.co/QufcPI9dm0
#biosimilars #healthcare #pharmacybenefits #benefits
Stanton Mehr retweeted
Thanks Stan for moderating The value of interchangeability panel. There is no clinical indication for an interchangeable biosimilar.
First panel discussion at #festivalofbiologicsusa: Do we learn anything new from phase 3 clinical studies for #biosimilars? Not that we don't already know. Don't require human clinical trials if you don't expect to learn anything, says @GillianWoollett. @LeahChristl
Stanton Mehr retweeted
Replying to @Celltrioninc
@Celltrionhc FDA application for subQ #infliximab filed: Could be big trouble for #biosimilar competitors. #biosimilars wp.me/p7gt6c-6Xp
Stanton Mehr retweeted
#GlobalBiosimilarsWeek officially starts this week, and today we're focusing on the value #biosimilars provide for patients around the globe.
Visit our Biosimilars #PatientResourceCenter to find educational resources: biosimilarsresources.org/
globalbiosimilarsweek.org/20…
Stanton Mehr retweeted
“Having a good standard in place speeds the process up, it helps the industry.” —Ronald Piervincenzi, PhD, CEO, @USPharmacopeia at #GRxBiosims 2022. #generics #biosimilars @DLeonard_DC
Stanton Mehr retweeted
The countdown begins! IGBA will host its third annual #GlobalBiosimilarsWeek Nov 14-18 to raise awareness of the powerful impact of #biosimilars for patients, medical professionals and health care systems. Download the social toolkit and join the movement! globalbiosimilarsweek.org/20…
Stanton Mehr retweeted
Don’t miss out on the #biosimilars industry’s premier scientific & regulatory event of 2022.
Join us at #GRxBiosims in North Bethesda, MD from November 7-9 to learn invaluable information & insights on generics and biosimilars from industry experts.
grxbiosims.org/
Stanton Mehr retweeted
Useful review of how ambiguities in Inflation Reduction Act #IRA could hurt #biosimilar development
Pretty clear that Congress did not grasp differences between biosimilars and generic drugs, IMHO
@StanMehr
drugch.nl/3fiZbCN
Stanton Mehr retweeted
Highly recommended! New @Amgen 2022 #Biosimilars Trend Report (free)
Loads of neat data by therapeutic class.
In big categories, ASPs are now down -60% or more
drugch.nl/3rMSUCr


























